PPIAP7: A Potential Drug Target and Biomarker for the treatment of Muscular Dystrophy

Target Name: PPIAP7

NCBI ID: G5489

PPIAP7

Other Name(s): Peptidylprolyl isomerase (cyclophilin) pseudogene 7 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene 7 | peptidylprolyl isomerase A pseudogene 7 | Peptidylprolyl isomerase A pseudogene 7 | PPIP7

PPIAP7: A Potential Drug Target and Biomarker for the treatment of Muscular Dystrophy

Muscular dystrophy is a group of genetic disorders characterized by progressive muscle weakness and degenerative changes. It affects millions of people worldwide, ranging from early-onset to late-stage cases. Although several treatments have been developed to manage muscle dystrophy, the majority of patients continue to experience significant quality of life (QoL) improvements. Therefore, there is a growing interest in identifying new therapeutic targets and biomarkers for the treatment of muscular dystrophy.

PPIAP7, a pseudogene for the enzyme peptidylprolyl isomerase (C cyclophilin), is a promising candidate for the treatment of muscular dystrophy due to its unique mechanism of action. In this article, we will discuss the biology of PPIAP7, its potential as a drug target, and its potential as a biomarker for the diagnosis and prognosis of muscular dystrophy.

Biochemistry and Function

PPIAP7 is a single-chain protein with 21 amino acid residues, located within the cytosol ofositol transporter (CST)尾. It has a calculated pI of 9.95 and a predicted localization in the endoplasmic reticulum (ER) and nuclear pore complex (NPC). PPIAP7 is a non-catalytic subunit of the cyclophilin enzyme, which is responsible for the conversion of inositol trisphosphate (IP3) to IP4 and IP6. This process is critical for intracellular signaling and the regulation of various cellular processes, including cell signaling, DNA replication, and protein synthesis.

The functional relevance of PPIAP7 is its involvement in the regulation of IP3-dependent intracellular signaling pathways. IP3 is a second messenger that plays a crucial role in intracellular signaling, particularly in the regulation of protein synthesis and cell signaling. It is generated from the breakdown of inositol by the IP3 kinase, which is a critical enzyme involved in the intracellular signaling pathway known as the second messenger signaling cascade.

The role of PPIAP7 in IP3-dependent signaling pathway is to regulate the activity of the IP3 kinase. Several studies have demonstrated that PPIAP7 can inhibit the activity of the IP3 kinase, thereby inhibiting IP3 production and downstream signaling. This unique mechanism of action makes PPIAP7 a potential drug target for the treatment of muscular dystrophy.

Drug Target Potential

The potential drug targets for PPIAP7 are numerous and diverse. Its involvement in IP3-dependent signaling pathway makes it a potential target for diseases characterized by the overproduction or dysfunction of IP3, such as neurodegenerative diseases, cancer, and muscle dystrophy.

1. Neurodegenerative Diseases: PPIAP7 has been shown to regulate the production of IP3 in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, targeting PPIAP7 may be a promising strategy for the development of new neurodegenerative disease treatments.
2. Cancer: PPIAP7 has been shown to regulate IP3 production in various types of cancer, including breast, ovarian, and prostate cancer. Therefore, targeting PPIAP7 may be a promising strategy for the development of new cancer treatments.
3. Muscular Dystrophy: As discussed above, PPIAP7 has been shown to regulate IP3 production in muscle dystrophy, which may be a potential target for the development of new muscular dystrophy treatments.

In addition to its potential drug targets, PPIAP7 also has the potential to serve as a biomarker for the diagnosis and prognosis of various diseases. Its involvement in IP3-dependent signaling pathway makes it a potential biomarker for the regulation of intracellular signaling pathways, including IP3 signaling. Therefore, measuring the levels of PPIAP7 in biological fluids, such as urine, plasma, or tissue, may be a promising strategy for the diagnosis and prognosis of various diseases.

Conclusion

PPIAP

Protein Name: Peptidylprolyl Isomerase A Pseudogene 7

The "PPIAP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets